Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 215
Gene Symbol: ABCD1
ABCD1
0.010 GeneticVariation group BEFREE The CCALD, which is caused by a mutation of the ABCD1 gene that encodes a peroxisomal membrane protein, progresses to a stage where the patient is in a vegetative state and can cause death within 3-5 yr after the appearance of neurological symptoms. 19496984 2011
Entrez Id: 43
Gene Symbol: ACHE
ACHE
0.020 Biomarker group BEFREE Hypersensitivity to acetylcholinesterase inhibitors (anti-AChEs) causes severe nervous system symptoms under low dose exposure. 10814709 2000
Entrez Id: 43
Gene Symbol: ACHE
ACHE
0.020 Biomarker group BEFREE This study aims to determine the degree of acetylcholinesterase inhibition and neurological symptoms for each of the psychiatric disorders diagnosed in the farm workers of a rural population in the state of Baja California, Mexico. 30813607 2019
Entrez Id: 54
Gene Symbol: ACP5
ACP5
0.010 Biomarker group BEFREE ACP5 deficiency is known to cause spondyloenchondrodysplasia (SPENCD), which is characterized by various autoimmune and neurological symptoms in addition to short stature. 26789720 2016
Entrez Id: 59
Gene Symbol: ACTA2
ACTA2
0.010 GeneticVariation group BEFREE Neonatal onset of neurologic symptoms in ACTA2 mutations has not been previously reported. 22752479 2013
Entrez Id: 60
Gene Symbol: ACTB
ACTB
0.010 Biomarker group BEFREE In conclusion, we demonstrate that PHEV utilizes the integrin α5β1-FAK-Rac1/Cdc42-PAK-LIMK-cofilin pathway to cause an actin cytoskeletal rearrangement to promote its own invasion, providing theoretical support for the development of PHEV pathogenic mechanisms and new antiviral targets.<b>IMPORTANCE</b> PHEV, a member of the <i>Coronaviridae</i> family, is a typical neurotropic virus that primarily affects the nervous system of piglets to produce typical neurological symptoms. 30541856 2019
Entrez Id: 95
Gene Symbol: ACY1
ACY1
0.010 Biomarker group BEFREE Most individuals known to be affected by ACY1 deficiency have presented with neurologic symptoms. 26686503 2016
Entrez Id: 11093
Gene Symbol: ADAMTS13
ADAMTS13
0.030 Biomarker group BEFREE Systematic testing of ADAMTS13 activity and anti-ADAMTS13 antibodies in patients who present with neurological symptoms and thrombocytopenia, in the presence of antiphospholipid antibodies, may help with the diagnosis of the rare thrombotic thrombocytopenic purpura-antiphospholipid syndrome combination. 27898514 2017
Entrez Id: 11093
Gene Symbol: ADAMTS13
ADAMTS13
0.030 Biomarker group BEFREE The association highlighted between loss of VWF-HMWM, detectable anti-ADAMTS13 IgG and neurological symptoms may offer new insights to understanding the pathophysiology of acquired auto-immune TTP. 31330376 2019
Entrez Id: 11093
Gene Symbol: ADAMTS13
ADAMTS13
0.030 Biomarker group BEFREE The increased awareness and availability of ADAMTS13 testing has also made it possible to detect atypical presentations of TTP such as patients with macrovascular neurological symptoms without accompanying hematological findings as well as help diagnose other causes of thrombotic microangiopathies e.g. atypical hemolytic uremic syndrome. 23420593 2013
Entrez Id: 103
Gene Symbol: ADAR
ADAR
0.010 GeneticVariation group BEFREE Only three cases with neurological disorders have been reported, although more than 50 mutations of the ADAR1 gene causing DSH have been reported and none of them had any neurological symptoms. 19017046 2008
Entrez Id: 576
Gene Symbol: ADGRB2
ADGRB2
0.010 GeneticVariation group BEFREE A de novo C-terminal mutation (R1465W) in the adhesion GPCR BAI2 (also known as ADGRB2) was identified in a patient suffering from progressive spastic paraparesis and other neurological symptoms. 28891236 2017
Entrez Id: 54806
Gene Symbol: AHI1
AHI1
0.010 GeneticVariation group BEFREE Furthermore, five patients with NPHP1 mutations carried the AHI1 variant R830W, which was predicted to be "possibly damaging" and was found with significantly higher frequency than in healthy control subjects and in patients with NPHP1 mutations without neurologic symptoms (five of 26 versus four of 276 and three of 152 alleles; P < 0.001 and P < 0.002, respectively). 17409309 2007
Entrez Id: 102157402
Gene Symbol: AK6
AK6
0.010 Biomarker group BEFREE The pathogenicity of the novel mycobacterium and its clinical significance are not certain, as the neurological symptoms of the patient could also be due to concomitant infection with Cryptococcus neoformans.The name Mycobacterium doricum sp. nov. is proposed for the novel mycobacterium; the type strain is strain FI-13295T (= DSM 44339T = CIP 106867T). 11760941 2001
Entrez Id: 211
Gene Symbol: ALAS1
ALAS1
0.010 AlteredExpression group BEFREE Acute porphyric attacks, precipitated by fasting, certain hormones and some drugs, involve induction of 5-ALAS secondarily to depletion of the above pool, and the resultant elevation of 5-ALA levels initiates the abdominal and neurological symptoms of attacks. 31443750 2019
Entrez Id: 224
Gene Symbol: ALDH3A2
ALDH3A2
0.010 AlteredExpression group BEFREE Sjögren-Larsson syndrome is a rare disorder that consists of congenital ichthyosis and neurological symptoms due to an enzymatic defect of fatty aldehyde dehydrogenase in the fatty alcohol cycle. 11978568 2002
Entrez Id: 7915
Gene Symbol: ALDH5A1
ALDH5A1
0.300 Biomarker group CTD_human Toxicologic/transport properties of NCS-382, a γ-hydroxybutyrate (GHB) receptor ligand, in neuronal and epithelial cells: Therapeutic implications for SSADH deficiency, a GABA metabolic disorder. 29031482 2018
Entrez Id: 301
Gene Symbol: ANXA1
ANXA1
0.010 AlteredExpression group BEFREE The Annexin A1 protein was constitutively expressed in all plaques, and Annexin A1 gene expression was statistically higher in patients with asymptomatic disease compared with those with neurological symptoms (87 ± 4% vs. 42 ± 6.2%; p < 0.001, unpaired t-test). 21195640 2011
Entrez Id: 8546
Gene Symbol: AP3B1
AP3B1
0.010 GeneticVariation group BEFREE HPS2 caused by mutations in AP3B1A leads to a highly overlapping phenotype without the neurologic symptoms. 26744459 2016
Entrez Id: 361
Gene Symbol: AQP4
AQP4
0.020 Biomarker group BEFREE AQP4-Ab-positive patients were more likely to have neurological symptoms (<i>P</i> = 0.002), less likely to experience dermatological manifestations (<i>P</i> = 0.045), and less likely to have detectable anti-dsDNA antibodies (<i>P</i> = 0.022). 31213132 2019
Entrez Id: 361
Gene Symbol: AQP4
AQP4
0.020 Biomarker group BEFREE Although the patient initially recovered with the reduction of anti-aquaporin-4 antibodies during treatment with intravenous methylprednisolone infusion and plasma exchange, her neurological symptoms deteriorated soon after the completion of plasma exchange. 28427692 2017
Entrez Id: 367
Gene Symbol: AR
AR
0.010 GeneticVariation group BEFREE SBMA exclusively affects adult males, whereas females homozygous for the AR mutation do not manifest neurological symptoms. 22609045 2012
Entrez Id: 383
Gene Symbol: ARG1
ARG1
0.010 Biomarker group BEFREE In contrast to other urea cycle defects, arginase 1 deficiency usually does not cause catastrophic neonatal hyperammonemia but rather presents with progressive neurological symptoms including seizures and spastic paraplegia in the first years of life and hepatic pathology, such as neonatal cholestasis, acute liver failure, or liver fibrosis. 26123990 2015
Entrez Id: 407
Gene Symbol: ARR3
ARR3
0.010 Biomarker group BEFREE A newly developed CAR-T-specific neurological symptom checklist (NSC) was completed by caregivers at 3 designated time-points. 30048343 2018
Entrez Id: 410
Gene Symbol: ARSA
ARSA
0.070 GeneticVariation group BEFREE Inherited functional deficiencies of ASA cause the lysosomal storage disease (LSD) metachromatic leukodystrophy (MLD), which is characterized by intralysosomal accumulation of sulfatide, progressive neurological symptoms and early death. 21515587 2011